Roswell Park Cancer Institute has once again been named to Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs, an annual list of centers that are national leaders in patient care, cancer outcomes and research.

An unprecedented network of centers collaborating to share information and translate these pooled resources into personalized treatments for cancer patients has expanded to 16 institutions with the addition of Roswell Park Comprehensive Cancer Center as a member.

New research led by a team from Roswell Park Comprehensive Cancer Center and published in the journal Nature Methods reports the development of genetically encoded GTP sensors that can rapidly detect changes in GTP levels in living cells.

Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment that causes shooting or burning pain, numbness, tingling and cold sensitivity of the hands and feet for many cancer patients.